Adalimumab News and Research

RSS
Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.
How have inflammatory bowel disease treatments changed after the introduction of biologics?

How have inflammatory bowel disease treatments changed after the introduction of biologics?

Are antidrug antibodies reducing the effectiveness of rheumatoid arthritis treatment?

Are antidrug antibodies reducing the effectiveness of rheumatoid arthritis treatment?

"Smart" sutures can detect inflammation and release drugs

"Smart" sutures can detect inflammation and release drugs

Clinical trial findings may be a game changer in the treatment of pediatric Crohn's disease

Clinical trial findings may be a game changer in the treatment of pediatric Crohn's disease

Study suggests mRNA vaccines decouple SARS-CoV-2 immunity from autoantibody responses observed during acute COVID-19

Study suggests mRNA vaccines decouple SARS-CoV-2 immunity from autoantibody responses observed during acute COVID-19

Study shows how arthritis affects people's working lives

Study shows how arthritis affects people's working lives

New treatment guidelines published for anorectal abscess, anal fistula, and rectovaginal fistula

New treatment guidelines published for anorectal abscess, anal fistula, and rectovaginal fistula

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

People with inflammatory immune conditions had increased risk of COVID-19-related death before vaccination

People with inflammatory immune conditions had increased risk of COVID-19-related death before vaccination

Trial shows the efficacy of anti-TNF drug for patients with early-stage Dupuytren's disease

Trial shows the efficacy of anti-TNF drug for patients with early-stage Dupuytren's disease

Research provides a roadmap for new therapies to treat chorioamnionitis

Research provides a roadmap for new therapies to treat chorioamnionitis

Intensive treatment for patients with Crohn's disease found to be safe

Intensive treatment for patients with Crohn's disease found to be safe

Biosimilars could drive down drug prices and lead to $38.4 billion savings

Biosimilars could drive down drug prices and lead to $38.4 billion savings

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Hidradenitis suppurativa: Discontinuation of adalimumab prior to surgery is not necessary

Hidradenitis suppurativa: Discontinuation of adalimumab prior to surgery is not necessary

Study analyzes uveitis risk after antirheumatic drug withdrawal in children with arthritis

Study analyzes uveitis risk after antirheumatic drug withdrawal in children with arthritis

Patient support program for painful conditions may also help avoid use of risky opioids

Patient support program for painful conditions may also help avoid use of risky opioids

Shifts in care due to COVID-19 pandemic likely to drive drug expenditures in 2021

Shifts in care due to COVID-19 pandemic likely to drive drug expenditures in 2021

New trial to evaluate anti-TNF drug as a treatment for COVID-19 patients begins

New trial to evaluate anti-TNF drug as a treatment for COVID-19 patients begins